PLIANT THERAPEUTICS, INC. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Pliant Therapeutics reported Q2 2026 net loss of $22.4M (vs. $43.3M prior year), with R&D expenses down 48% to $16.7M and G&A down 47% to $7.1M, primarily due to headcount reductions after terminating bexotegrast development in 2025. FORTIFY Phase 1b trial of lead candidate PLN-101095 for ICI-refractory tumors is enrolling ahead of schedule across three cohorts (up to 102 patients); interim data expected 2027. Company appointed two oncology leaders to board: Flavia Borellini (25+ years targeted oncology development) and Robert Iannone (EVP R&D/CMO at Jazz Pharmaceuticals). Cash position of $159.6M (cash + short-term investments) expected to fund operations into H2 2028.
Why this rating
Strong trial enrollment and experienced board adds credibility, but company is pre-revenue clinical-stage. Burn rate ~$45M annually; cash runway to H2 2028 is adequate but not extensive. Modest positive signals insufficient to offset execution risk in oncology.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.